Sustained Release Excipients Market Size & Growth Forecast 2027–2036, By Segments (Product, Technology, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Sustained Release Excipients Market size was more than USD 1.7 billion in 2026 and is set to grow at a 7.98% CAGR between 2027 and 2036, crossing USD 3.66 billion by 2036. The industry revenue for 2027 is calculated at USD 1.81 billion.
Get more details on this report
Request Free Sample ReportSustained Release Excipients Market Intelligence Snapshot
Regional Market Dynamics
- North America led the market in 2026 due to its mature pharmaceutical manufacturing base, established formulation expertise, and consistent adoption of controlled-release drug formulations in commercial production.
- Asia Pacific is projected to grow at a 9.49% CAGR, driven by expanding pharmaceutical manufacturing, greater use of advanced formulations, and rising investment in modified-release drug development.
Segment Momentum
- Polymers held a 47.59% share in 2026 because they provide consistent control over drug release, support established manufacturing processes, and help developers create convenient extended-release formulations.
- Transdermal is the fastest-growing technology as demand rises for non-invasive drug delivery systems that improve patient convenience, adherence, and sustained therapeutic exposure.
Market Expansion Drivers
- Growing demand for controlled-release formulations improving patient compliance in chronic disease treatment.
- Expanding geriatric and pediatric populations increasing adoption of sustained-release oral dosage systems.
- Rising partnerships in advanced oral drug delivery technologies accelerating excipient innovation pipelines.
Leading Market Participants
- Top companies in the sustained release excipients market include BASF SE (Germany), Evonik Industries AG (Germany), Ashland Inc. (United States), International Flavors & Fragrances Inc. (United States), Croda International Plc (United Kingdom), Gattefossé SAS (France), Merck KGaA (Germany), Roquette Frères S.A. (France), Colorcon Inc. (United States), DuPont de Nemours, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.7 billion
- 2027 Estimated Market Size: USD 1.81 billion.
- Projected Market Size: USD 3.66 billion by 2036
- Growth Forecast: 7.98% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Polymers (Product) | Targeted Delivery (Technology) | Oral (Route of Administration)
- Emerging Opportunity Segment: Polymers (Product) | Transdermal (Technology) | Transdermal (Route of Administration)
Market Growth Drivers and Industry Trends
Growing demand for controlled-release formulations improving patient compliance in chronic disease treatment
The sustained release excipients market will benefit from the increasing use of controlled-release drug formulations designed to maintain therapeutic effects over extended periods and simplify medication schedules for patients managing chronic conditions. Sustained-release excipients regulate the release of active pharmaceutical ingredients within dosage forms, helping reduce fluctuations in drug concentrations and potentially limiting the frequency of administration. As pharmaceutical developers focus on improving adherence and optimizing treatment regimens for long-term therapies, excipients with reliable release-controlling, matrix-forming, and drug-delivery properties are becoming increasingly important. Their incorporation into oral dosage formulations also supports the development of products that provide consistent drug release while accommodating different active ingredients and formulation requirements.
Expanding geriatric and pediatric populations increasing adoption of sustained-release oral dosage systems
Demographic changes are creating stronger demand for dosage forms that are easier to administer and better suited to the needs of patients at different stages of life, supporting the sustained release excipients market. Geriatric patients frequently manage multiple medications and may benefit from simplified dosing schedules, while pediatric formulations require careful consideration of dosage flexibility, palatability, and controlled drug exposure. Sustained-release oral systems can help address some of these formulation requirements by extending drug release and reducing the need for frequent administration. Excipients that provide predictable swelling, diffusion, matrix formation, and dissolution characteristics are therefore receiving greater attention in the development of age-appropriate pharmaceutical formulations.
Rising partnerships in advanced oral drug delivery technologies accelerating excipient innovation pipelines
Collaboration between pharmaceutical developers, excipient manufacturers, and drug delivery specialists is strengthening innovation in advanced oral dosage technologies, creating new opportunities for the sustained release excipients market. Partnerships allow participants to combine formulation expertise, material science capabilities, and drug delivery technologies to develop excipients that provide more precise control over active ingredient release. Such collaborative development can support the optimization of polymer systems, functional coatings, matrix technologies, and other excipient platforms for different therapeutic applications. Increased cooperation across the pharmaceutical value chain is also helping accelerate formulation development by enabling technical evaluation and adaptation of excipient systems to complex drug characteristics.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing demand for sustained-release drug formulations | 2.80% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Technological innovations in excipient formulations | 2.80% | Medium term (2–5 yrs) | North America, Asia Pacific | Low | Moderate |
| Expansion of pharmaceutical manufacturing in emerging markets | 2.80% | Long term (5+ yrs) | Asia Pacific, Latin America | Low | Slow |
| Growing demand for controlled-release formulations improving patient compliance in chronic disease treatment | 2.20% | High | North America, Europe | High | Near Term |
| Expanding geriatric and pediatric populations increasing adoption of sustained-release oral dosage systems | 1.90% | Moderate | Asia Pacific, North America | High | Mid Term |
| Rising partnerships in advanced oral drug delivery technologies accelerating excipient innovation pipelines | 1.60% | Moderate | North America, Europe, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the leading position in the sustained release excipients market in 2026, supported by an advanced pharmaceutical manufacturing ecosystem, strong demand for controlled-release drug formulations, and substantial investment in drug delivery innovation. The region benefits from sophisticated formulation research, stringent quality requirements, and widespread adoption of technologies designed to improve therapeutic consistency and patient adherence. Growing demand for oral dosage forms with extended drug action, together with the expanding development of complex and specialty medicines, supports the use of functional excipients that enable controlled drug release. Established regulatory and manufacturing capabilities further reinforce regional demand for high-performance excipient solutions.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing regional market, driven by expanding pharmaceutical production, improving healthcare access, and increasing investment in local drug manufacturing capabilities. The region's growing generic medicines industry and rising demand for more sophisticated oral formulations are creating broader opportunities for sustained release technologies. Improvements in pharmaceutical research infrastructure, formulation expertise, and manufacturing standards are also encouraging the adoption of advanced excipients. In addition, increasing healthcare expenditure and the need for convenient dosage regimens are supporting pharmaceutical developers in incorporating controlled-release approaches into a wider range of therapies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Formulation Quality FocusGermany prioritizes sustained release excipients that enhance product consistency and manufacturing efficiency in pharmaceutical development. Companies continue investing in advanced formulation technologies that support reliable therapeutic performance and regulatory expectations.
France 🇫🇷
Controlled Release DevelopmentFrance supports sustained release excipient adoption through ongoing pharmaceutical formulation innovation and specialty medicine development. Manufacturers prioritize excipients that improve dosage performance while meeting evolving regulatory and quality standards.
Italy 🇮🇹
Generic Formulation EnhancementItaly utilizes sustained release excipients to strengthen the development of value-added generic medicines and specialty pharmaceutical products. Drug manufacturers increasingly adopt advanced excipient technologies to improve formulation efficiency and therapeutic consistency.
Japan 🇯🇵
Precision Delivery SolutionsJapan emphasizes sustained release excipients for innovative pharmaceutical formulations requiring precise drug release profiles. Pharmaceutical developers increasingly integrate advanced excipient technologies to improve patient convenience and product differentiation.
South Korea 🇰🇷
Biopharma Formulation SupportSouth Korea expands the use of sustained release excipients across innovative pharmaceuticals and contract manufacturing activities. Companies focus on excipient performance, formulation flexibility, and efficient production to support competitive drug development programs.
United States 🇺🇸
Advanced Drug FormulationThe U.S. sustained release excipients market is driven by pharmaceutical companies developing differentiated oral and injectable therapies. Manufacturers increasingly seek excipients that improve controlled drug delivery while supporting scalable and compliant production processes.
Segment Leadership and Growth Trends
Sustained Release Excipients Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Polymers (Largest & Fastest-Growing Segment)
The polymers segment dominated the sustained release excipients market in 2026, accounting for 47.59%, while also representing the fastest-growing product category. Polymers are widely used in controlled-release formulations because their physical and chemical properties can be tailored to regulate the release of active pharmaceutical ingredients over extended periods. Their ability to support controlled drug dissolution, improve dosing consistency, and enhance formulation performance makes them particularly valuable in sustained-release dosage forms. Increasing demand for therapies that improve patient convenience and treatment adherence is encouraging pharmaceutical manufacturers to adopt advanced excipient systems. Continued formulation innovation and the development of specialized polymer matrices are further expanding their application across oral and other controlled-release drug delivery formats.
Technology Segment Analysis: Targeted Delivery (Largest Segment) vs Transdermal (Fastest-Growing Segment)
The targeted delivery segment represented the largest share of the sustained release excipients market in 2026, accounting for 24.6%, supported by growing interest in delivering therapeutic agents more effectively to specific sites or biological targets. Targeted delivery technologies can improve treatment precision while helping optimize drug exposure and reduce unnecessary systemic effects, making them increasingly attractive for complex therapeutic formulations. Rising demand for patient-centric drug delivery, advances in formulation science, and increasing emphasis on improving therapeutic outcomes are strengthening adoption. The growing development of sophisticated pharmaceutical formulations is also creating opportunities for excipients that can provide controlled and targeted release characteristics.
The transdermal segment is expected to witness the fastest growth as pharmaceutical developers increasingly seek non-invasive delivery approaches that can provide sustained and consistent drug administration. Transdermal systems can offer advantages such as reduced dosing frequency, improved patient convenience, and avoidance of certain limitations associated with oral administration. Advances in skin-permeation technologies, formulation development, and controlled-release materials are broadening the range of active ingredients that can potentially be delivered through the skin. Increasing interest in patient-friendly drug administration and the development of advanced therapeutic delivery systems are consequently supporting greater adoption of transdermal technologies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan | Polymers | Polymers |
| Technology | Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation, Others | Targeted Delivery | Transdermal |
| Route of Administration | Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Others | Oral | Transdermal |
Competitive Landscape and Market Positioning
Leading companies in the sustained release excipients market:
1. BASF SE (Germany)
2. Evonik Industries AG (Germany)
3. Ashland Inc. (United States)
4. International Flavors & Fragrances Inc. (United States)
5. Croda International Plc (United Kingdom)
6. Gattefossé SAS (France)
7. Merck KGaA (Germany)
8. Roquette Frères S.A. (France)
9. Colorcon Inc. (United States)
10. DuPont de Nemours Inc. (United States)
The sustained release excipients market is growing with rising demand for advanced drug delivery systems. Formulation innovation is improving controlled-release performance and patient compliance. The sustained release excipients market continues to expand as pharmaceutical development becomes more targeted and efficient.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| BASF SE (Germany) | |||||||
| Evonik Industries AG (Germany) | |||||||
| Ashland Inc. (United States) | |||||||
| International Flavors & Fragrances Inc. (United States) | |||||||
| Croda International Plc (United Kingdom) | |||||||
| Gattefossé SAS (France) | |||||||
| Merck KGaA (Germany) | |||||||
| Roquette Frères S.A. (France) | |||||||
| Colorcon Inc. (United States) | |||||||
| DuPont de Nemours Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Croda International Plc | Jun-23 | Croda International Plc commenced construction of a 23,680 square feet pharmaceutical excipients manufacturing facility in Pennsylvania, United States. The expansion is intended to increase production capacity for drug delivery ingredients, supporting growing demand for functional excipients used in controlled and sustained-release pharmaceutical formulations and strengthening regional supply capabilities. |
| DuPont, International Flavors & Fragrances Inc | Feb-21 | DuPont completed the merger of its Nutrition & Biosciences business with International Flavors & Fragrances Inc, consolidating its position in functional ingredients and delivery systems. The integration expanded the excipients portfolio, including controlled-release technologies, and strengthened downstream capabilities in pharmaceutical and nutraceutical formulation solutions. |
| Colorcon Inc, DuPont | Apr-19 | Colorcon Inc entered a Controlled Release Alliance with DuPont to expand its functional film coating portfolio through the addition of Aquacoat modified-release products. The collaboration strengthens controlled-release formulation capabilities in pharmaceutical excipients, enhancing availability of advanced coating technologies used to improve drug delivery performance and formulation flexibility. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Sustained Release Excipients Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Excipient Function | Matrix Formers, Coating & Membrane Formers, Release Modifiers, Mucoadhesive Agents |
| Therapeutic Area | Cardiovascular Diseases, Diabetes & Metabolic Disorders, Oncology, Central Nervous System Disorders, Gastrointestinal Disorders, Other Therapeutic Areas |
| Drug Formulation Type | Generic Formulations, Branded Formulations, Over-the-Counter Formulations, Specialty & Complex Formulations |
Sustained Release Excipients Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Excipient Innovation Roadmap |
|
| Pharma Outsourcing Opportunity Assessment |
|
| Supplier Qualification & Risk Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow large is the sustained release excipients market?
How is the sustained release excipients industry expected to grow over the next 10 years?
How is demand for controlled-release formulations influencing excipient selection strategies?
Why are partnerships becoming important for innovation in the sustained release excipients market?
Why do polymers lead the sustained release excipients market?
Which technology segment is growing fastest in the sustained release excipients market?
Why does North America lead the sustained release excipients market?
Which region is expected to grow fastest in the sustained release excipients market?
Who holds a significant market share in the sustained release excipients landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization